Latest Hotspot

The FDA is evaluating the revised NDA for TransCon PTH (Palopegteriparatide) for adult hypoparathyroidism

21 December 2023
3 min read

Ascendis Pharma A/S has made a public statement that the U.S. Food and Drug Administration (FDA) has acknowledged and is in the process of evaluating the resubmitted New Drug Application of the company's TransCon PTH(palopegteriparatide), which is aimed at addressing the medical condition of hypoparathyroidism in adult individuals.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The office recognized the renewed submission as a comprehensive, tier 2 reply and designated a target date of May 14, 2024, under the guidelines of the Prescription Drug User Fee Act. In the United States, TransCon PTH (palopegteriparatide) remains experimental as a prodrug version of parathyroid hormone aimed at treating adult individuals living with hypoparathyroidism.

"The FDA's continuing evaluation of TransCon PTH is an encouraging step, and we anticipate further collaboration with the office throughout this process," stated Jan Mikkelsen, the President and Chief Executive Officer of Ascendis Pharma. "We are dedicated to promptly providing TransCon PTH to the American citizens, especially considering the critical needs yet to be met within the hypoparathyroidism population."

Ascendis Pharma is employing its inventive TransCon technology framework to establish itself as a front-runner and fully comprehensive biopharmaceutical entity, with a dedication to significantly improve patient welfare. The maiden authorization of Palopegteriparatide is anticipated by November 2023, with the European Union poised to be the initial district to consent to the drug. It implies the medication is presently under the scrutiny of regulatory oversight to confirm its safety and effectiveness for patient use.

Palopegteriparatide has achieved expedited inspection status, underscoring its urgency as a remedy capable of satisfying a critical healthcare void. Furthermore, it has received recognition as an orphan drug, signifying its aim to counteract a less common medical condition.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面

中度可信度描述已自动生成

According to the data provided by the Synapse Database, As of December 19, 2023, there are 4 investigational drugs for the CaSR and PTH1R target, including 2 indications, 6 R&D institutions involved, with related clinical trials reaching 17, and as many as 75 patents.

Palopegteriparatide appears to be a promising drug in the field of endocrinology and metabolic disease, specifically for the treatment of hypoparathyroidism. Its development has progressed to the highest phase globally, with approval expected in the near future. The drug's regulatory status as a priority review and orphan drug further highlights its potential significance in addressing unmet medical needs.

图形用户界面, 文本, 网站

描述已自动生成

Understanding Proteases Inhibitors and Methods to Keep Abreast of Their Recent Developments
Understanding Proteases Inhibitors and Methods to Keep Abreast of Their Recent Developments
21 December 2023
Protease inhibitors are drugs that inhibit proteases, enzymes crucial in various biological processes.
Read →
Vertex Reports Encouraging Outcomes in Early Trial of New Drug VX-548 for Alleviating Diabetes-Related Nerve Pain
Latest Hotspot
3 min read
Vertex Reports Encouraging Outcomes in Early Trial of New Drug VX-548 for Alleviating Diabetes-Related Nerve Pain
21 December 2023
Vertex Pharmaceuticals Incorporated declared favorable outcomes from its Phase 2 trial assessing various dosages of the targeted NaV1.8 inhibitor, VX-548, in individuals suffering from painful diabetic peripheral neuropathy.
Read →
Does the Risk management systems  need to be updated regularly?
Knowledge Base
2 min read
Does the Risk management systems need to be updated regularly?
21 December 2023
If the applicant / marketing authorisation holder has submitted an RMP for the product, the RMP submitted later should adopt an updated format.
Read →
Wugen Reveals Early Data on WU-CART-007 for Tough Blood Cancers at Annual American Hematology Conference
Latest Hotspot
3 min read
Wugen Reveals Early Data on WU-CART-007 for Tough Blood Cancers at Annual American Hematology Conference
21 December 2023
Wugen Unveils Initial Results from Early-Stage Clinical Assessment of WU-CART-007 in Hard-to-Combat Hematologic Malignancies at the Yearly American Hematology Conference.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.